Skip to main content
. 2020 Jan 30;34:146–156. doi: 10.1016/j.molmet.2020.01.010

Figure 1.

Figure 1

T39 ASO reduces hepatic lipogenic gene expression and dietary obesity. Female and male Ldlr−/− mice were treated with a T39 ASO or control ASO and given a western diet (WTD). A) Liver lipogenic gene expression as measured by qRT-PCR and normalized to actin and GAPDH expression and liver triglyceride (TG), cholesterol (CHOL), and phopholipid (PL) content in female mice after 20 weeks WTD. Body weight measured weekly and final gonadal adipose tissue weight (gWAT) in B) female and C) male mice on WTD for 12 weeks. D) Lipoprotein cholesterol and triglycerides in female mice after 20 weeks WTD. Data represent mean ± SEM (A) or SD (B–D), n = 10 mice/group, *p < 0.05, **p < 0.01, ***p < 0.001 compared with control ASO.